Arch Biopartners, Inc. ARCH

TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company’s pre-IND IL-32 chronic kidney disease (“CKD”) program. The U.S.-based lab was selected for its core competencies in the areas required to support the IL-32 program. It will perform studies on behalf of Arch to generate proprietary data and support the Company’s patent portfolio c

LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on t

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the 2026 American Diabetes Association Thought Leadership Series at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films. The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innova

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS). Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canad

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury in patients undergoing on-pump cardiac surgery. Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the ninth site to be activated globally for the

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company’s human trial f

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 CAD per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”). The proceeds of the Offering will be used by Arch as general working capital and for certain operating expenses that are not covered by the Company’s human t

Arch Biopartners (ARCH.V) said Friday that St. Michael's Hospital (SMH) in Toronto, has begun patien

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity Health Toronto, has commenced patient dosing in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). St. Michael’s Hospital is the third Canadian site to successfully recruit patients in the CS-AKI Phase II tria